Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE on NYSE American) on February 25, 2022. The registrant is an emerging growth company incorporated in Delaware. Note: The request metadata referenced "Serina Therapeutics, Inc.," but the filing text explicitly identifies the registrant as AgeX Therapeutics, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a specific corporate governance event regarding executive compensation.
Material Changes
The material change reported is an adjustment to executive compensation:
- Event: Approval of salary increases for certain employees.
- Specific Officer: Andrea Park, Chief Financial Officer.
- Change Details: An annual salary increase of $18,250.
- Effective Date: March 1, 2022.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors detailed in the company's periodic SEC reports. No specific business outlook, guidance, or new risk factors were introduced in this document.
Investor Verification Checklist
- Verify the correct registrant name is AgeX Therapeutics, Inc., not Serina Therapeutics, Inc.
- Confirm the effective date of the CFO's salary increase is March 1, 2022.
- Review the company's most recent 10-K or 10-Q for comprehensive financial health data, as this 8-K contains no financial metrics.
- Check for any other pending compensation adjustments for "certain employees" mentioned but not detailed in this summary.